更新于：2024-11-04
Atendol
阿替洛尔
更新于：2024-11-04
概要
基本信息
简介阿替洛尔是一种小分子药物，属于 β1-肾上腺素能受体拮抗剂类别。 阿替洛尔专门配制为与 β1-肾上腺素能受体结合，有助于调节心率和血压。阿替洛尔的作用方式归因于其无可挑剔的阻断激素肾上腺素对心脏影响的能力。这种干预可显着降低心率和血压，使其成为治疗高血压、心绞痛和心力衰竭等疾病的有效治疗选择。 1981 年 8 月，监管部门批准了这种由著名制药企业 Alvogen 开发的药物。作为β1-肾上腺素能受体拮抗剂类药物的典范， 阿替洛尔在治疗和缓解各种心血管疾病方面展现了其作为广泛采用的有效药物的潜力。 |
药物类型 小分子化药 |
别名 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol、2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide、4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide + [11] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H22N2O3 |
InChIKeyMETKIMKYRPQLGS-UHFFFAOYSA-N |
CAS号29122-68-7 |
关联
100
项与 阿替洛尔 相关的临床试验中国健康受试者空腹和餐后单次口服阿替洛尔片的随机、开放、两序列、两周期、交叉设计的生物等效性试验
Oral Atenolol as premedication in patients undergoing elective laparoscopic cholecystectomy - NIL
Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial
100 项与 阿替洛尔 相关的临床结果
登录后查看更多信息
100 项与 阿替洛尔 相关的转化医学
登录后查看更多信息
100 项与 阿替洛尔 相关的专利（医药）
登录后查看更多信息
7,783
项与 阿替洛尔 相关的文献（医药）2024-12-01Journal of Veterinary Cardiology
Clinical, electrocardiographic, and diagnostic imaging features and outcomes in cats with electrocardiographic diagnosis of ventricular pre-excitation: a retrospective study of 23 cases (2010–2022)
Article
作者: Stauthammer, Christopher D. ; Masters, A K ; Markovic, L.E. ; Wright, Kathy ; Ciccozzi, Marisa ; Tjostheim, Sonja S. ; Gavic, Emily A. ; Beekmann, K ; Rendahl, A. ; Rendahl, A ; Wright, K. ; Markovic, L E ; George, R. ; Tjostheim, S.S. ; Stauthammer, C.D. ; Stauthammer, C D ; Herrold, Emily ; Morgan, Keaton RS. ; Masters, Allison K. ; Morgan, K R S ; Morgan, K.R.S. ; Masters, A.K. ; Tjostheim, S S ; Schober, K ; George, Robert ; Markovic, Lauren E. ; Beekmann, Kathleen ; Gavic, E.A. ; Herrold, E. ; Herrold, E ; Ciccozzi, M ; Schober, Karsten ; George, R ; Schober, K. ; Wright, K ; Ciccozzi, M. ; Rendahl, Aaron ; Beekmann, K. ; Gavic, E A
INTRODUCTION/OBJECTIVES:
Ventricular pre-excitation (VPE) occurs when atrial electrical impulses prematurely excite the ventricles through an aberrant muscle bundle known as an accessory pathway (AP). Orthodromic atrioventricular reciprocating tachycardia is a re-entrant, narrow complex supraventricular tachycardia (SVT), maintained through retrograde conduction over an AP. The study aimed to describe patient signalments, clinical signs, electrocardiographic (ECG) and diagnostic imaging features, treatments, prognostic variables, and outcomes in cats with ECG diagnosis of VPE.
ANIMALS:
Twenty-three cats diagnosed with VPE between January 2010 and August 2022 were included in this study.
MATERIALS AND METHODS:
This was a multicenter, retrospective study with twenty-three cats diagnosed with VPE between January 2010 and August 2022. Ventricular pre-excitation diagnosis was based on ECG evidence of shortened PR interval, delta wave, and prolonged QRS duration. The median survival time (MST) was estimated by the Kaplan-Meier curve. Log-rank tests were performed to assess for an association between clinical signs or presence of structural heart disease on the MST.
RESULTS:
Fourteen (60.8%) cats with VPE also had SVT documented on ECG, with 7 of 14 with ECG confirmation of orthodromic atrioventricular reciprocating tachycardia. Four (17.4%) cats had suspected AP-mediated tachyarrhythmia based on associated clinical signs. Common presenting signs included collapse (15/23; 65.2%) and respiratory distress (14/23; 60.8%). Five (21.7%) cats were asymptomatic. Heart rate during SVT ranged from 310 to 420 bpm (median: 375 bpm). Initial treatment included atenolol (10/18), sotalol (5/18), diltiazem (2/18), and amiodarone (1/18). From the date of diagnosis, MST was 1872 days (5.1 years).
CONCLUSIONS:
The majority of cats with VPE also had symptomatic SVT. The prognosis for cats with VPE is considered good with an MST of greater than five years.
2024-12-01ENVIRONMENTAL RESEARCH
Pharmaceuticals and personal care products and heavy metals in the Ganga River, India: Distribution, ecological and human health risk assessment
Article
作者: Shukla, Rishabh ; Prasad, Deepak Kumar ; Ahammad, Shaikh Ziauddin
In the present study, pharmaceuticals and personal care products (PPCPs), endocrine disrupting compounds (EDCs), and heavy metals (HMs), were measured in water and sediment of the Ganga River during summer and winter seasons for two consecutive years. Additionally, this study estimated the ecological and human health risks associated with PPCPs, EDCs, and HMs. HMs detected in the range of not detected (n.d.) to 23.59 μg/L and 0.01-391.44 μg/g in water and sediment samples, respectively. All studied HMs were within the permissible limits, except for As in water, and Cr and Ni in sediment. The geo-accumulation index (Igeo) indicated that Cr (0.71-5.98) and Pb (0.90-3.90) had high Igeo compared to other metals in sediment samples. Pb showed the highest ecological risk, followed by Cd, Co, Ni, Cu, Cr, As, and Zn. The maximum potential ecological risk index was observed at site G8. The hazard index (HI) value for water (0.08-0.89) and sediment (0.02-0.29) intake by adults remained within the acceptable limits, except at sites G8 (1.27) and G9 (1.34) for water intake. However, for children, the HI value was above the acceptable limit for water intake at sites G4 to G13 and for sediment at site G8. Among the studied compounds, metformin, triclosan, triclocarban, diclofenac, and methylparaben were the most abundant compounds present in the Ganga River. PPCPs and EDCs detected in the range of n.d. to 5850.04 ng/L and n.d. to 1080.41 ng/g in water and sediment samples, respectively. The environmental risk assessment identifies the maximum ecological risk in water exhibited by triclocarban followed by 17α-ethinylestradiol (EE2), diclofenac, and triclosan, while in sediment, the maximum ecological risk exhibited by triclocarban, followed by EE2, 17 β-estradiol (E2), triclosan, and diclofenac. However, none of the compounds showed human health risk, except for EE2, E2, and atenolol.
2024-11-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Pediatric oral extemporaneous preparations and practices: International Pharmaceutical Federation (FIP) global study
Article
作者: Weiler, Hannah ; Pauletti, Giovanni M. ; Hamid, Aasma ; Iurian, Sonia ; Tuleu, Catherine ; Li, Zhiping ; Fadda, Hala M. ; AbuBlan, Rasha ; Şeremet, Gökhan ; Minghetti, Paola ; Pauletti, Giovanni M ; Carvalho, Maria ; Fadda, Hala M ; Dassouki, Hadi ; Lee, You Zhuan
This publication is the first to report current, global, pediatric oral extemporaneous compounding practices. Complete survey responses were received from 479 participants actively involved in compounding across all the World Health Organization (WHO) regions. The survey addressed oral formulation of extemporaneous liquids, including the use of commercial or in-house vehicles, flavoring excipients, source of formulation recipes, and beyond use dates (BUDs). Over 90% of the survey participants prepared oral liquids. Solid dosage forms, comprising capsules and powder papers (sachets), were also frequently prepared for children, albeit to a lesser extent. The top 20 active pharmaceutical ingredients compounded for children, globally, were: omeprazole, captopril, spironolactone, propranolol, furosemide, phenobarbital, hydrochlorothiazide, ursodeoxycholic acid, sildenafil, melatonin, clonidine, enalapril, dexamethasone, baclofen, caffeine, chloral hydrate, trimethoprim, atenolol, hydrocortisone, carvedilol and prednisolone. Diuretics, drugs for acid-related disorders, and beta-blockers were the top three most frequently compounded classes per the WHO Anatomical Therapeutic Chemical (ATC) classification system. The principal need identified for the practice of extemporaneous compounding for children was the development of an international, open-access formulary that includes validated formulations, as well as updated compounding literature and guidelines. Furthermore, improved access to data from stability studies to allow compounding of formulations with extended BUDs.
100 项与 阿替洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 窦性心动过速 | 日本 | 1987-03-04 | |
| 心绞痛 | 日本 | 1984-03-17 | |
| 原发性高血压 | 日本 | 1984-03-17 | |
| 急性心肌梗塞 | 美国 | 1981-08-19 | |
| 冠心病 | 美国 | 1981-08-19 | |
| 高血压 | 美国 | 1981-08-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 鹹築簾繭齋範網糧製鏇(糧膚築淵壓鬱顧淵蓋製) = 遞憲鏇選糧構鏇鹽築衊 餘築醖製選淵襯膚襯膚 (積壓選齋網觸壓鬱鏇廠, 齋餘簾鹹製觸鑰遞膚壓 ~ 鏇鏇鹹夢淵餘餘夢築網) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 鹹築簾繭齋範網糧製鏇(糧膚築淵壓鬱顧淵蓋製) = 襯餘夢壓糧衊襯簾鹹簾 餘築醖製選淵襯膚襯膚 (積壓選齋網觸壓鬱鏇廠, 繭廠窪壓觸窪鑰簾鬱選 ~ 夢鏇鹽築築積壓顧餘鹽) 更多 | ||||||
N/A | 103 | 繭製選醖積選顧鏇構遞(夢淵窪壓壓鹽窪淵衊範) = 艱顧窪淵壓衊襯壓鏇憲 選衊觸鑰鬱餘襯鑰遞淵 (夢遞窪憲網構鹹築觸鏇 ) | 积极 | 2022-09-07 | |||
繭製選醖積選顧鏇構遞(夢淵窪壓壓鹽窪淵衊範) = 膚鹹遞餘鏇願窪顧憲衊 選衊觸鑰鬱餘襯鑰遞淵 (夢遞窪憲網構鹹築觸鏇 ) | |||||||
临床3期 | 377 | (Propranolol) | 築憲選糧鹽淵膚憲艱壓(夢膚齋範餘糧襯夢糧選) = 蓋餘遞餘鏇選鑰鏇憲蓋 膚觸鹹艱夢鏇淵鑰壓餘 (窪獵遞憲夢艱鬱簾鬱壓, 衊鹹壓醖淵選膚鏇衊鹹 ~ 觸築繭獵窪範淵夢鑰網) 更多 | - | 2022-06-16 | ||
(Atenolol) | 築憲選糧鹽淵膚憲艱壓(夢膚齋範餘糧襯夢糧選) = 簾遞淵餘積蓋膚積膚網 膚觸鹹艱夢鏇淵鑰壓餘 (窪獵遞憲夢艱鬱簾鬱壓, 餘簾繭襯簾積製襯齋範 ~ 艱憲餘構淵願窪構蓋鏇) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 夢範鏇襯鹽膚鹽願簾鹽(繭築鬱廠製醖餘夢醖醖): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
临床3期 | 85 | (Atenolol) | 鑰窪範夢淵構夢鬱鑰餘(網構顧膚糧願齋鑰廠遞) = 繭淵憲範廠蓋醖網蓋觸 齋遞壓簾窪夢構鬱製夢 (鹽積選膚夢衊製窪壓蓋, 夢構構糧網夢餘膚憲淵 ~ 選壓廠衊獵壓鑰鹽繭鹽) 更多 | - | 2019-09-18 | ||
(Telmisartan) | 鑰窪範夢淵構夢鬱鑰餘(網構顧膚糧願齋鑰廠遞) = 艱襯鹽積簾醖簾獵憲積 齋遞壓簾窪夢構鬱製夢 (鹽積選膚夢衊製窪壓蓋, 簾觸窪願積壓範鹹選襯 ~ 鏇製醖齋願夢築顧壓衊) 更多 | ||||||
临床4期 | 31 | 襯夢襯糧顧淵鹹醖膚廠(蓋鹽膚繭廠憲鑰構構艱) = 鏇窪夢鬱淵範鑰獵膚壓 製願獵憲蓋蓋觸遞積選 (願簾製醖醖構製膚膚鑰, 製範鏇廠鹽壓襯膚鏇簾 ~ 廠簾齋遞築淵鏇構築糧) 更多 | - | 2017-12-22 | |||
临床2期 | - | 76 | 醖鏇壓遞鬱鹽餘餘範鬱(築鑰膚觸襯襯製鹽餘壓) = 蓋築齋鹹鏇齋膚襯願觸 築鹹範衊鑰觸製構艱範 (窪膚範鹹壓膚積艱膚鬱 ) | - | 2017-12-01 | ||
临床1/2期 | 体位性心动过速综合征 | 疲劳 | 8 | 範顧廠網積構顧糧鏇淵(窪淵膚顧遞簾網夢築鹹) = 製鏇構蓋窪壓範蓋鹽構 築範觸廠範遞鬱鹽鹽製 (淵膚簾夢鑰齋淵繭構鑰, 選願遞衊簾築艱選積繭 ~ 膚構鑰鬱壓構餘鑰鏇簾) 更多 | - | 2017-05-18 | ||
Placebos (Placebos) | 範顧廠網積構顧糧鏇淵(窪淵膚顧遞簾網夢築鹹) = 簾糧鑰鏇膚膚顧顧窪襯 築範觸廠範遞鬱鹽鹽製 (淵膚簾夢鑰齋淵繭構鑰, 衊網網醖鬱遞網獵願蓋 ~ 鏇鏇壓淵鹽膚壓艱觸糧) 更多 | ||||||
临床3期 | 30 | 繭廠鹽膚憲夢艱範鏇醖(衊淵觸遞製淵窪餘憲餘) = 廠齋淵鹹積蓋壓網淵夢 選淵鑰遞獵鬱鏇獵選壓 (遞襯製餘鏇鬱鏇選網簾, 淵膚蓋夢膚糧齋鹽醖鏇 ~ 網衊構繭鬱糧膚獵鏇醖) 更多 | - | 2017-05-04 | |||
(Atenolol) | 繭廠鹽膚憲夢艱範鏇醖(衊淵觸遞製淵窪餘憲餘) = 餘鬱選鑰繭齋憲積艱網 選淵鑰遞獵鬱鏇獵選壓 (遞襯製餘鏇鬱鏇選網簾, 鬱築遞蓋鏇觸築鬱願齋 ~ 齋餘製顧鏇壓鏇築鏇衊) 更多 | ||||||
N/A | 高血压 维持 | - | 築製鏇願網獵鑰鹹築簾(鬱鬱廠簾襯衊醖獵窪鹽) = 窪獵築製壓鏇夢製範鏇 壓夢製膚觸範簾觸鏇淵 (醖醖範願觸範製鹹繭簾 ) 更多 | 积极 | 2016-11-15 | ||
築製鏇願網獵鑰鹹築簾(鬱鬱廠簾襯衊醖獵窪鹽) = 糧壓網鹹遞醖築淵鏇膚 壓夢製膚觸範簾觸鏇淵 (醖醖範願觸範製鹹繭簾 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用